Cargando…

Retrospective Study of Ellipsoid Zone Integrity Following Treatment with Intravitreal Ocriplasmin (OZONE Study)

PURPOSE: To assess generalized (GD) and focal ellipsoid zone disruption (FD) in patients with symptomatic vitreomacular adhesion (sVMA) using spectral domain optical coherence tomography (SD-OCT) following ocriplasmin. PATIENTS AND METHODS: OZONE was a Phase 4, retrospective study of patients with s...

Descripción completa

Detalles Bibliográficos
Autores principales: Drenser, Kimberly A, Pieramici, Dante J, Gunn, Joseph M, Rosberger, Daniel F, Kozma, Petra, Fineman, Mitchell S, Duchateau, Luc, Khanani, Arshad M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291832/
https://www.ncbi.nlm.nih.gov/pubmed/34295149
http://dx.doi.org/10.2147/OPTH.S285464
_version_ 1783724719591129088
author Drenser, Kimberly A
Pieramici, Dante J
Gunn, Joseph M
Rosberger, Daniel F
Kozma, Petra
Fineman, Mitchell S
Duchateau, Luc
Khanani, Arshad M
author_facet Drenser, Kimberly A
Pieramici, Dante J
Gunn, Joseph M
Rosberger, Daniel F
Kozma, Petra
Fineman, Mitchell S
Duchateau, Luc
Khanani, Arshad M
author_sort Drenser, Kimberly A
collection PubMed
description PURPOSE: To assess generalized (GD) and focal ellipsoid zone disruption (FD) in patients with symptomatic vitreomacular adhesion (sVMA) using spectral domain optical coherence tomography (SD-OCT) following ocriplasmin. PATIENTS AND METHODS: OZONE was a Phase 4, retrospective study of patients with sVMA treated with a single intravitreal injection of ocriplasmin (0.125 mg). Data from adult patients with at least 6-month follow-up after ocriplasmin were included. SD-OCT was performed at baseline (within 30 days before ocriplasmin), before Day 21 post-injection (early observation, EO), and by last observation (LO) which was maximally 6 months post-injection. The main outcome measure was the development of new and the evolution of existing FD/GD at EO and LO. RESULTS: The study enrolled 134 eyes/patients from 22 sites in the USA. At baseline, 87 eyes (64.9%) had FD, 21 eyes (15.7%) had GD and 26 eyes (19.4%) had no FD/GD. Among the eyes without FD/GD at baseline, 13 (50%) and 8 (30.8%) developed FD or GD, respectively, by EO. By LO, FD/GD improvement or resolution was seen in >80% of these eyes. Among the eyes with FD/GD at baseline, <40% had improving/resolving EZ integrity at LO. The absence of FD/GD at baseline was associated with less persistent FD/GD at LO (P<0.0005). The presence of FD with MH at baseline was associated with persistent FD at LO (P=0.027). CONCLUSION: The fact that a large majority of eyes had FD/GD prior to ocriplasmin was unexpected and demonstrates that EZ disruptions are common in sVMA. This suggests that loss of EZ integrity may be part of the natural history of this disorder. It is hypothesized that the status of the EZ at baseline is a contributing, ocriplasmin independent modulator of subsequent EZ changes after ocriplasmin. Prospective analyses which include a sham control group would be required to test this hypothesis.
format Online
Article
Text
id pubmed-8291832
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82918322021-07-21 Retrospective Study of Ellipsoid Zone Integrity Following Treatment with Intravitreal Ocriplasmin (OZONE Study) Drenser, Kimberly A Pieramici, Dante J Gunn, Joseph M Rosberger, Daniel F Kozma, Petra Fineman, Mitchell S Duchateau, Luc Khanani, Arshad M Clin Ophthalmol Clinical Trial Report PURPOSE: To assess generalized (GD) and focal ellipsoid zone disruption (FD) in patients with symptomatic vitreomacular adhesion (sVMA) using spectral domain optical coherence tomography (SD-OCT) following ocriplasmin. PATIENTS AND METHODS: OZONE was a Phase 4, retrospective study of patients with sVMA treated with a single intravitreal injection of ocriplasmin (0.125 mg). Data from adult patients with at least 6-month follow-up after ocriplasmin were included. SD-OCT was performed at baseline (within 30 days before ocriplasmin), before Day 21 post-injection (early observation, EO), and by last observation (LO) which was maximally 6 months post-injection. The main outcome measure was the development of new and the evolution of existing FD/GD at EO and LO. RESULTS: The study enrolled 134 eyes/patients from 22 sites in the USA. At baseline, 87 eyes (64.9%) had FD, 21 eyes (15.7%) had GD and 26 eyes (19.4%) had no FD/GD. Among the eyes without FD/GD at baseline, 13 (50%) and 8 (30.8%) developed FD or GD, respectively, by EO. By LO, FD/GD improvement or resolution was seen in >80% of these eyes. Among the eyes with FD/GD at baseline, <40% had improving/resolving EZ integrity at LO. The absence of FD/GD at baseline was associated with less persistent FD/GD at LO (P<0.0005). The presence of FD with MH at baseline was associated with persistent FD at LO (P=0.027). CONCLUSION: The fact that a large majority of eyes had FD/GD prior to ocriplasmin was unexpected and demonstrates that EZ disruptions are common in sVMA. This suggests that loss of EZ integrity may be part of the natural history of this disorder. It is hypothesized that the status of the EZ at baseline is a contributing, ocriplasmin independent modulator of subsequent EZ changes after ocriplasmin. Prospective analyses which include a sham control group would be required to test this hypothesis. Dove 2021-07-16 /pmc/articles/PMC8291832/ /pubmed/34295149 http://dx.doi.org/10.2147/OPTH.S285464 Text en © 2021 Drenser et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Clinical Trial Report
Drenser, Kimberly A
Pieramici, Dante J
Gunn, Joseph M
Rosberger, Daniel F
Kozma, Petra
Fineman, Mitchell S
Duchateau, Luc
Khanani, Arshad M
Retrospective Study of Ellipsoid Zone Integrity Following Treatment with Intravitreal Ocriplasmin (OZONE Study)
title Retrospective Study of Ellipsoid Zone Integrity Following Treatment with Intravitreal Ocriplasmin (OZONE Study)
title_full Retrospective Study of Ellipsoid Zone Integrity Following Treatment with Intravitreal Ocriplasmin (OZONE Study)
title_fullStr Retrospective Study of Ellipsoid Zone Integrity Following Treatment with Intravitreal Ocriplasmin (OZONE Study)
title_full_unstemmed Retrospective Study of Ellipsoid Zone Integrity Following Treatment with Intravitreal Ocriplasmin (OZONE Study)
title_short Retrospective Study of Ellipsoid Zone Integrity Following Treatment with Intravitreal Ocriplasmin (OZONE Study)
title_sort retrospective study of ellipsoid zone integrity following treatment with intravitreal ocriplasmin (ozone study)
topic Clinical Trial Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291832/
https://www.ncbi.nlm.nih.gov/pubmed/34295149
http://dx.doi.org/10.2147/OPTH.S285464
work_keys_str_mv AT drenserkimberlya retrospectivestudyofellipsoidzoneintegrityfollowingtreatmentwithintravitrealocriplasminozonestudy
AT pieramicidantej retrospectivestudyofellipsoidzoneintegrityfollowingtreatmentwithintravitrealocriplasminozonestudy
AT gunnjosephm retrospectivestudyofellipsoidzoneintegrityfollowingtreatmentwithintravitrealocriplasminozonestudy
AT rosbergerdanielf retrospectivestudyofellipsoidzoneintegrityfollowingtreatmentwithintravitrealocriplasminozonestudy
AT kozmapetra retrospectivestudyofellipsoidzoneintegrityfollowingtreatmentwithintravitrealocriplasminozonestudy
AT finemanmitchells retrospectivestudyofellipsoidzoneintegrityfollowingtreatmentwithintravitrealocriplasminozonestudy
AT duchateauluc retrospectivestudyofellipsoidzoneintegrityfollowingtreatmentwithintravitrealocriplasminozonestudy
AT khananiarshadm retrospectivestudyofellipsoidzoneintegrityfollowingtreatmentwithintravitrealocriplasminozonestudy